Home » Topics » Regulatory » EMA

EMA
RSS

CHMP grants positive opinion for labeling update to Relvar Ellipta in patients with asthma

Jan. 29, 2018

EMA accepts patisiran MAA for hereditary ATTR amyloidosis

Jan. 26, 2018

Santhera anticipates negative CHMP opinion on appeal for MAA for Raxone

Jan. 25, 2018

U.S. priority review and E.U. accelerated assessment granted for Kymriah

Jan. 17, 2018

EMA accepts Evenity MAA in osteoporosis

Jan. 8, 2018

EMA gives orphan drug designation to Spruce Biosciences' SPR-001

Jan. 8, 2018

EMA accepts CMA application for avacopan for ANCA-associated vasculitis

Jan. 4, 2018

Cascadian Therapeutics receives pediatric investigation plan waiver from EMA for tucatinib

Jan. 3, 2018

BiondVax Pharmaceuticals planning phase III study of universal flu vaccine

Dec. 29, 2017

EMA committee recommends against approval of Aplidin for multiple myeloma.

Dec. 19, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...